
Dec 15 (Reuters) - Palvella Therapeutics Inc PVLA.O:
PALVELLA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF CUTANEOUS VENOUS MALFORMATIONS, A SERIOUS, RARE GENETIC DISEASE WITH NO FDA-APPROVED THERAPIES
PALVELLA THERAPEUTICS INC - 73% OF PARTICIPANTS IMPROVED IN PHASE 2 TRIAL
PALVELLA THERAPEUTICS INC - QTORIN™ RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS